AML

(redirected from acute myelogenous leukemia)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

Adjustable Rate Mortgage

A mortgage with an interest rate that changes periodically. Generally speaking, an adjustable rate mortgage is linked to some major benchmark rate; for example, the interest rate may be stated as "LIBOR + 1%." The mortgage may or may not have a cap on how much the interest rate can rise or fall, or on how often the interest rate may change. Very often, the initial interest rate for an adjustable-rate mortgage is lower than that for a fixed-rate mortgage. This allows more people to qualify for an adjustable-rate mortgage; however, this kind of mortgage can be risky because the interest rate (and therefore the monthly payment) can rise unexpectedly. Indeed the prevalence of ARMs has been blamed for the housing bubble in the mid-2000s and the subsequent recession. See also: Credit Crunch, Teaser Rate.

Anti-Money Laundering

Any law or regulation requiring an institution to perform due diligence on potential clients to ensure that it is not aiding in a money laundering scheme. If the institution does not conduct due diligence properly, it may be held legally liable for the money laundering activities. These regulations were an important part of the USA PATRIOT Act.

AML

See adjustable mortgage loan.
References in periodicals archive ?
Table 57: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Annual Cost of Treatment ($), 2004-2011 76
The database also includes pharmaceutical companies, biotech companies, CROs, hospitals, government labs and other organisations active in the Acute Myelogenous Leukemia research field.
The company has three drug programs in clinical development, INNO-406, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, small cell lung cancer, and acute myelogenous leukemia.
Top 20 companies in late stage Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Projects
Vion has two agents in clinical trials: Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in: (i) a Phase III trial in combination with cytarabine in relapsed acute myelogenous leukemia and (ii) a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia.
Troxatyl(TM) is an anti-cancer agent currently in acute myelogenous leukemia (AML) clinical trials.
Eleos' lead drug, cenersen (EL625), is currently in a Phase II trial in acute myelogenous leukemia (AML).
Food and Drug Administration for CLORETAZINE(TM) (VNP40101M) for the treatment of acute myelogenous leukemia.
A Food and Drug Administration advisory committee voted unanimously Friday to recommend that the agency approve the drug for use in patients being treated for Acute Myelogenous Leukemia.
In addition to the recently acquired Tamibarotene for acute promyelocytic leukemia, the company has three drug programs in clinical development, INNO-406, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, small cell lung cancer, and acute myelogenous leukemia respectively.
May 27 /PRNewswire/ -- Cigarette smoking has been linked to acute myelogenous leukemia, according to The Health Consequences of Smoking: A Report of the Surgeon General, released today.
The Phase 1 trial enrolled 17 patients with myelodysplastic syndromes (MDS), refractory acute myelogenous leukemia (AML) or CLL.
Full browser ?